Head-To-Head Analysis: Portage Biotech (NASDAQ:ALP) & International Business Machines (NYSE:IBM)

International Business Machines (NYSE:IBM) and Portage Biotech (NASDAQ:ALP) are both technology companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, profitability, institutional ownership, valuation, earnings and dividends.

Analyst Recommendations

This is a breakdown of recent ratings and price targets for International Business Machines and Portage Biotech, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
International Business Machines	1	11	16	0	2.54
Portage Biotech	1	2	0	0	1.67

International Business Machines presently has a consensus target price of $265.40, indicating a potential upside of 12.56%. Portage Biotech has a consensus target price of $0.25, indicating a potential upside of 47.75%. Given Portage Biotech’s higher possible upside, analysts clearly believe Portage Biotech is more favorable than International Business Machines.

Insider & Institutional Ownership

59.0% of International Business Machines shares are held by institutional investors. Comparatively, 13.4% of Portage Biotech shares are held by institutional investors. 0.3% of International Business Machines shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Volatility & Risk

International Business Machines has a beta of 0.7, meaning that its share price is 30% less volatile than the S&P 500. Comparatively, Portage Biotech has a beta of 0.61, meaning that its share price is 39% less volatile than the S&P 500.

Profitability

This table compares International Business Machines and Portage Biotech’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
International Business Machines	15.52%	35.65%	7.54%
Portage Biotech	N/A	N/A	N/A

Valuation & Earnings

This table compares International Business Machines and Portage Biotech”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
International Business Machines	$67.53 billion	3.29	$10.59 billion	$11.27	20.92
Portage Biotech	$100,000.00	39.71	-$38.63 million	($8.18)	-0.02

International Business Machines has higher revenue and earnings than Portage Biotech. Portage Biotech is trading at a lower price-to-earnings ratio than International Business Machines, indicating that it is currently the more affordable of the two stocks.

Summary

International Business Machines beats Portage Biotech on 12 of the 14 factors compared between the two stocks.

About International Business Machines

International Business Machines Corporation, together with its subsidiaries, provides integrated solutions and services worldwide. The company operates through Software, Consulting, Infrastructure, and Financing segments. The Software segment offers a hybrid cloud and AI platforms that allows clients to realize their digital and AI transformations across the applications, data, and environments in which they operate. The Consulting segment focuses on skills integration for strategy, experience, technology, and operations by domain and industry. The Infrastructure segment provides on-premises and cloud based server, and storage solutions, as well as life-cycle services for hybrid cloud infrastructure deployment. The Financing segment offers client and commercial financing, facilitates IBM clients’ acquisition of hardware, software, and services. The company has a strategic partnership to various companies including hyperscalers, service providers, global system integrators, and software and hardware vendors that includes Adobe, Amazon Web services, Microsoft, Oracle, Salesforce, Samsung Electronics and SAP, and others. The company was formerly known as Computing-Tabulating-Recording Co. International Business Machines Corporation was incorporated in 1911 and is headquartered in Armonk, New York.

About Portage Biotech

Portage Biotech Inc., together with its subsidiaries, researches and develops pharmaceutical and biotechnology products. The company’s product includes IMM60, an iNKT cell activator; IMM65, a PLGA-nanoparticle combined with a NY-ESO-1 peptide vaccine; INT230-6 that is in Phase I/II clinical trials for the treatment of solid tumors; STING, a small molecule that binds to the stimulator of interferon genes in cancer; CellPorter, a cell permeable peptide platform technology derived from human proteins; PPL-003, an ophthalmic solution; and SBI-101, a blood-conditioning technology to restore balance to the immune system after acute vital organ injury, such as acute kidney injury. It also focuses on nanolipogel technology for use in immune-oncology; and antibodies against a novel T-cell for use as a monotherapy and combination therapy for solid and haematological malignancies. In addition, the company develops antibodies implicated in the inflammatory tumor and tumor-infiltrating immune cell microenvironments; and FOXO4-P53 modulator and C-RAF inhibitor. Portage Biotech Inc. is based in Tortola, British Virgin Islands.